Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Lynn Connolly, M.D., Ph.D., Chief Medical Officer of Adagio Therapeutics, Inc.
(the "Company"), has resigned her position, effective as of March 25, 2022, to
tend to family obligations. Dr. Connolly will continue to serve as Chief Medical
Officer through the Company's previously announced analysis of the ADG20
clinical data from its global Phase 2/3 clinical trials for the prevention and
treatment of COVID-19 to assess the preliminary safety and efficacy of ADG20 at
the 300mg dose in each trial and to transition her responsibilities. Ellie
Hershberger, PharmD, the Company's Chief Development Officer, will assume
responsibility for the Company's clinical development programs on a permanent
basis. The Company expects to enter into a consulting agreement with
Dr. Connolly. The Company and its Board of Directors thank Dr. Connolly for her
contributions and wish her well in her future endeavors.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses